您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2014, Vol. 52 ›› Issue (S1): 77-79.

• 临床医学 • 上一篇    下一篇

晚期胃癌患者血清TP表达与含替吉奥方案化疗疗效的相关性研究

徐光辉1, 李玉1, 刘忠伦2, 胡楠1   

  1. 1. 连云港市第一人民医院 肿瘤科, 江苏 连云港 222002;
    2. 连云港市第一人民医院 检验科, 江苏 连云港 222002
  • 收稿日期:2014-11-30 发布日期:2014-12-30
  • 基金资助:
    连云港市卫生局课题(指令性1216)

Correlations between serum levels of TP and clinical outcome in patients with advanced gastric cancer receiving S-1 regimen chemotherapy

XU Guang-hui1, LI Yu1, LIU Zhong-lun2, HU Nan1   

  1. 1. Department of Oncological Chemotherapy, The First People's Hospital of Lianyungang , Lianyungang 222002, Jiangsu China;
    2. Department of Laboratory, The First People's Hospital of Lianyungang , Lianyungang 222002, Jiangsu China
  • Received:2014-11-30 Published:2014-12-30
  • Contact: 李玉, E-mail: ly651226@163.com E-mail:ly651226@163.com

PDF (PC)

77

摘要： 目的 探讨胸苷磷酸化酶(TP)在晚期胃癌患者血清中的表达及其与含替吉奥方案化疗疗效的相关性。方法 收集46例接受以替吉奥为基础的一线化疗方案治疗的晚期胃癌患者化疗前的血清标本,运用酶联免疫吸附试验(ELISA)方法检测血清中TP的表达水平,分析其与化疗疗效及预后的相关性。结果 肝脏转移患者TP表达水平低于无肝脏转移患者(P<0.01),TP高表达与低表达患者的临床获益率差异无统计学意义。TP高表达患者的中位无进展生存期(PFS)长于低表达患者(6.5个月vs 5.0个月,P＝0.026)。结论 以替吉奥为基础化疗的晚期胃癌患者中,TP高表达者预后相对较好。

关键词: 预后, 胸苷磷酸化酶, 胃癌, 替吉奥

Abstract: Objective To investigate the correlations between serum levels of TP and clinical outcome in patients with advanced gastric cancer receiving S-1 regimen chemotherapy. Methods Serum samples before chemotherapy were collected from 46 patients receiving first-line S-1 regimen chemotherapy from Jun 2012 to Jan 2014, TP levels were analyzed using ELISA assay. Results TP expressions were significantly lower in patients with liver metastasis than those in patients without liver metastasis (P<0.01). There was no difference in clinical beneficial rate (CBR) between patients with high and low levels of TP. The median progression-free survival (PFS) in patients with high level of TP was longer than those with low level of TP (6.5 m vs 5.0 m,P=0.026 ). Conclusion In patients receiving first-line S-1 regimen chemotherapy, those with high level of TP may get better prognosis than those with low level of TP.

Key words: Gastric cancer, Thymidine phosphorylase, S-1, Prognosis

中图分类号: 

  • R735
[1] 夏传生,李娜萍,李明显,等.胸苷磷酸化酶及血管内皮生长因子在胃腺癌组织中的表达及其临床意义[J].华中科技大学学报: 医学版,2011,40(3): 343-346.
[2] Hata K,Fujiwaki R,Nakayama K,et al.Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor [J].Anticancer Res,1999,20(5C): 3941-3949.
[3] Fujiwaki R,Hata K,Nakayama K,et al.Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer[J].J Clin Oncol,2000,18(23): 3946-3951.
[4] Matsuura T,Kuratate I,Teramachi K,et al.Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas[J].Cancer Res,1999,59(19): 5037-5040.
[5] Takebayashi Y,Miyadera K,Akiyama S,et al.Expression of thymidine phosphorylase in human gastric carcinoma[J].Cancer Science,1996,87(3): 288-295.
[6] Fujioka S,Yoshida K,Yanagisawa S,et al.Angiogenesis in pancreatic carcinoma [J].Cancer,2001,92(7): 1788-1797.
[7] 何琼,高静,王婷婷,等.晚期胃癌患者血清 TS、TP 表达水平与氟尿嘧啶为基础的化疗疗效及预后的相关性[J].中国癌症杂志,2013,23(4): 292-297.
[8] Nishimura G,Terada I,Kobayashi T,et al.Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy [J].Oncol Rep,2002,9(3): 479-482.
[9] Zhou J,Xiao Y S,Tang Z Y,et al.Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration [J].J Cancer Res Clin Oncol,2005,131(8): 547-551.
[1] 栗英林,宋道庆,徐忠华. 应用生物信息学方法分析肾透明细胞癌中FKBP11的表达[J]. 山东大学学报 (医学版), 2020, 1(9): 45-51.
[2] 史爽,李娟,米琦,王允山,杜鲁涛,王传新. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报 (医学版), 2020, 1(7): 47-52.
[3] 路璐,孙志钢,张楠. 继发性嗜血细胞综合征1例[J]. 山东大学学报 (医学版), 2020, 1(7): 122-124.
[4] 李星凯,刘战业,姜运峰,李军. 原发性中央型和周围型肺鳞癌临床病理学及预后差异[J]. 山东大学学报（医学版）, 2017, 55(9): 73-78.
[5] 宗帅,肖东杰,刘华,郏雁飞,马晓丽,李焕杰,黎娉,郑燕,汪运山. CSN5在胃癌中的表达及与患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(7): 12-16.
[6] 孙启晶,陈方方,李春晓,张才擎. PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值[J]. 山东大学学报（医学版）, 2017, 55(4): 55-59.
[7] 董尧,宋亚林,田涛,高建国. 确诊8年未经治疗却无明显进展的阴茎恶性黑色素瘤1例报道[J]. 山东大学学报（医学版）, 2017, 55(3): 125-126.
[8] 林家香,郭子嘉,苏鹏,王晓,郭雅欣,吴晓娟,相磊,周志强, 王妍,崔秀杰,潘爱凤,郭成浩. 致癌蛋白CIP2A在乳腺导管上皮恶变中的作用及预测浸润性导管癌患者预后的能力[J]. 山东大学学报（医学版）, 2017, 55(3): 100-106.
[9] 周兰兰,潘学谊,郭煜. 48例急性混合细胞表型白血病患者的临床特征及预后[J]. 山东大学学报（医学版）, 2017, 55(2): 79-83.
[10] 张希英,翟春颜,李劲松,韩博. 中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系[J]. 山东大学学报（医学版）, 2017, 55(2): 84-91.
[11] 刘惠苓,王兴文,冯少滨,冯虹,韩俊庆. B类I型清道夫受体的高表达与结肠癌患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(10): 84-89.
[12] 李晓宁,崔连群. 急性心肌梗死合并多支血管病变患者非梗死相关动脉处理的时机[J]. 山东大学学报（医学版）, 2016, 54(8): 50-54.
[13] 王雯,刘尧,龙飞,马卫霞,苏莉莉. 外周血淋巴细胞/单核细胞比值与恶性胸膜间皮瘤患者预后的关系[J]. 山东大学学报（医学版）, 2016, 54(8): 72-77.
[14] 刘童,张欣,王传新. IRX5 mRNA在结直肠癌诊断及预后中的价值[J]. 山东大学学报（医学版）, 2016, 54(7): 69-74.
[15] 郝姝桦,郏雁飞,郑燕,马晓丽,孔毅,黎娉,宗帅,张垚,汪运山. ARNT2在胃癌中的表达及临床意义[J]. 山东大学学报（医学版）, 2016, 54(7): 6-10.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发